NCT06053086 (SAHARA-04) is a NA clinical trial of Treatment ETHOS radiotherapy in Breast Cancer, sponsored by Institut du Cancer de Montpellier - Val d'Aurelle.

Who is sponsoring NCT06053086?

NCT06053086 is sponsored by Institut du Cancer de Montpellier - Val d'Aurelle.

What drugs are being tested in NCT06053086?

Interventions in NCT06053086: Treatment ETHOS radiotherapy, Conventional IMRT.

What condition does NCT06053086 study?

NCT06053086 studies Breast Cancer.

Is NCT06053086 still recruiting?

NCT06053086 is currently recruiting now. Last updated 12 March 2026.

Last reviewed 2026-03-12 · How we verify

NCT06053086: SAHARA-04

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SAHARA-04 : Adaptive Radiotherapy in Hypersensitive Patients and High Locoregional Risk Breast Cancer With ETHOS Technology

Recruiting now NA Last updated 12 March 2026

What this trial tests

NA trial testing Treatment ETHOS radiotherapy in Breast Cancer in 500 participants. Currently enrolling.

Timeline

1 March 2025

Primary endpoint
30 November 2030

30 November 2030

Quick facts

Lead sponsor	Institut du Cancer de Montpellier - Val d'Aurelle
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	500
Start date	1 March 2025
Primary completion	30 November 2030
Estimated completion	30 November 2030
Sites	1 location across France

Drugs / interventions tested

Treatment ETHOS radiotherapy
Conventional IMRT

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Institut du Cancer de Montpellier - Val d'Aurelle — full company profile →

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

* Prospective, open-label, bi-center study, assessing the clinical outcomes of adaptive breast radiotherapy with ETHOS in hypersensitive patients. * Bi-centric with ETHOS center : ICM (Institut du Cancer de Montpellier) and ISC (Institut Sainte Catherine) Avignon * 500 patients will be included: * COHORTE A = Treatment ETHOS RT :46 evaluable patients with high risk of LRR and bf+ risk * COHORT B = Conventional IMRT : 454 others patients with high risk of LRR and bf- risk

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Institut du Cancer de Montpellier - Val d'Aurelle trials

Trials by the same sponsor.

NCT07523152 — Assessment of Sexual Quality of Life Following Local Treatment (Radiotherapy With or Without Surgery) in Patients With H · NA · not yet recruiting
NCT07198971 — Feasibility Study Incorporating Music Therapy to Optimise the Smoking Cessation Process Coordinated by a Tobacco Addicti · NA · recruiting
NCT07043543 — Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11) · NA · not yet recruiting
NCT07441941 — Single-Fraction Pulmonary Ablative Radiotherapy Outcomes and Quality-of-life Workup · recruiting
NCT06382818 — Personalization of Breast Radiotherapy According to Loco-regional Recurrence Risk and Toxicity Probability · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06053086 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut du Cancer de Montpellier - Val d'Aurelle
Last refreshed: 12 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06053086.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing